Strategic Financial Concepts LLC bought a new stake in Haleon plc (NYSE:HLN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 88,757 shares of the company's stock, valued at approximately $847,000.
Several other large investors have also recently bought and sold shares of the business. FMR LLC boosted its position in shares of Haleon by 5.8% during the 3rd quarter. FMR LLC now owns 104,918,269 shares of the company's stock worth $1,110,035,000 after acquiring an additional 5,768,117 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Haleon by 49.9% in the third quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company's stock valued at $96,833,000 after purchasing an additional 3,046,841 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Haleon by 25.3% in the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company's stock valued at $53,791,000 after purchasing an additional 1,026,939 shares in the last quarter. Natixis Advisors LLC increased its stake in Haleon by 142.5% in the third quarter. Natixis Advisors LLC now owns 1,473,767 shares of the company's stock valued at $15,593,000 after purchasing an additional 866,070 shares during the last quarter. Finally, Van ECK Associates Corp raised its holdings in Haleon by 13.5% during the fourth quarter. Van ECK Associates Corp now owns 3,509,400 shares of the company's stock worth $33,480,000 after purchasing an additional 418,609 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company's stock.
Shares of HLN opened at $9.98 on Wednesday. The company's 50 day simple moving average is $9.55 and its 200-day simple moving average is $9.81. The firm has a market cap of $45.15 billion, a PE ratio of 29.34, a price-to-earnings-growth ratio of 2.70 and a beta of 0.28. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.
Several research analysts have recently issued reports on the stock. Morgan Stanley cut shares of Haleon from an "overweight" rating to an "equal weight" rating in a report on Friday, January 10th. Sanford C. Bernstein downgraded shares of Haleon from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $10.95.
Check Out Our Latest Stock Analysis on HLN
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.